Ipsilateral breast tumor recurrence in early stage breast cancer patients treated with breast conserving surgery and adjuvant radiation therapy: Concordance of biomarkers and tumor location from primary tumor to in-breast tumor recurrence

doi:10.5306/wjco.v11.i1.20

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6846)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

492

WORD

255

HTML

4160

Tables (1-3)

355

Sum=5262

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

672

Download

902

Sum=1574

Jan 24, 2020 (publication date) through Feb 14, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Jan 24, 2020; 11(1): 20-30
Published online Jan 24, 2020. doi: 10.5306/wjco.v11.i1.20

Table 1 Clinicopathologic characteristics of primary tumors in patients who experienced an ipsilateral breast tumor recurrence

	Overall	DCIS	Invasive
n	37	19	18
Age [years, mean (SD)]	63.08 (14.52)	65.74 (11.49)	60.28 (17.05)
Race (%)
White	27 (73.0)	13 (68.4)	14 (77.8)
African American	7 (18.9)	3 (15.8)	4 (22.2)
Asian	1 (2.7)	1 (5.3)	0 (0.0)
Declined	2 (5.4)	2 (10.5)	0 (0.0)
ER Positive (%)	26 (70.3)	14 (73.7)	12 (66.7)
PR Positive (%)	24 (64.9)	12 (63.2)	12 (66.7)
ILC	2 (5.4)		2 (11.1)
IDC	15 (40.5)		15 (83.3)
Mixed invasive	1 (2.7)		1 (5.6)
Invasive only: DCIS present (%)
No			3 (16.7)
Yes			15 (83.3)
Invasive only: HER-2 Status (%)
Negative			14 (77.8)
Positive			3 (16.7)
Not performed			1 (5.6)
Invasive only: Pathologic grade (%)
1			4 (22.2)
2			4 (22.2)
3			10 (55.6)
Invasive only: Ki 67 Status (%)
Low (< 10)			8 (44.4)
High (≥ 10)			8 (44.4)
Not performed			2 (11.1)
Invasive only: LVI (%)
Not present			12 (66.7)
Present			5 (27.8)
Close			1 (5.6)
DCIS only: Nuclear grade (%)
Grade 1		0 (0)
Grade 2		10 (52.6)
Grade 3		9 (47.3)
T - stage (%)
0	19 (51.4)	19 (100.0)	0 (0.0)
1	11 (29.7)	0 (0.0)	11 (61.1)
2	7 (18.9)	0 (0.0)	7 (38.9)
Positive margins (%)	8 (21.6)	6 (31.6)	2 (11.1)
Chemotherapy (%)	11 (29.7)	0 (0.0)	11 (61.1)
Hormone therapy (%)	18 (48.6)	7 (36.8)	11 (61.1)
Tumor axis/quadrant (%)
3:00	1 (2.7)	1 (5.3)	0 (0.0)
6:00	1 (2.7)	0 (0.0)	1 (5.6)
9:00	1 (2.7)	1 (5.3)	0 (0.0)
Central	2 (5.4)	1 (5.3)	1 (5.6)
LIQ	1 (2.7)	0 (0.0)	1 (5.6)
LOQ	3 (8.1)	2 (10.5)	1 (5.6)
UIQ	6 (16.2)	2 (10.5)	4 (22.2)
UOQ	22 (59.5)	12 (63.2)	10 (55.6)

DCIS: Ductal carcinoma in situ; ER: Estrogen receptor; PR: Progesterone receptor; ILC: Invasive lobular carcinoma; IDC: Invasive ductal carcinoma; LVI: Lymphovascular invasion; LIQ: Lower inner quadrant; LOQ: Lower outer quadrant; UIQ: Upper inner quadrant; UOQ: Upper outer quadrant.

Citation: Purswani JM, Shaikh F, Wu SP, Kim JC, Schnabel F, Huppert N, Perez CA, Gerber NK. Ipsilateral breast tumor recurrence in early stage breast cancer patients treated with breast conserving surgery and adjuvant radiation therapy: Concordance of biomarkers and tumor location from primary tumor to in-breast tumor recurrence. World J Clin Oncol 2020; 11(1): 20-30
URL: https://www.wjgnet.com/2218-4333/full/v11/i1/20.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i1.20